[go: up one dir, main page]

Everolimus-eluting stents in interventional cardiology

Vasc Health Risk Manag. 2012:8:393-404. doi: 10.2147/VHRM.S23388. Epub 2012 Jun 27.

Abstract

Bare metal stents have a proven safety record, but limited long-term efficacy due to in-stent restenosis. First-generation drug-eluting stents successfully countered the restenosis rate, but were hampered by concerns about their long-term safety. Second generation drug-eluting stents have combined the low restenosis rate of the first generation with improved long-term safety. We review the evolution of drug-eluting stents with a focus on the safety, efficacy, and unique characteristics of everolimus-eluting stents.

Keywords: efficacy; everolimus-eluting stents; safety.

Publication types

  • Review

MeSH terms

  • Angioplasty, Balloon, Coronary / adverse effects
  • Angioplasty, Balloon, Coronary / instrumentation*
  • Cardiovascular Agents / administration & dosage*
  • Coronary Artery Disease / therapy*
  • Coronary Restenosis / etiology
  • Coronary Restenosis / prevention & control
  • Drug-Eluting Stents*
  • Everolimus
  • Humans
  • Patient Selection
  • Prosthesis Design
  • Risk Assessment
  • Risk Factors
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives*
  • Treatment Outcome

Substances

  • Cardiovascular Agents
  • Everolimus
  • Sirolimus